Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREV-NOSE: Nozin for Respiratory Virus Prevention in Stem Cell Transplant
NCT04060849Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in respiratory viral infection comparing Arm I (Nozin) with Arm II (Standard of Care) (2 arms). Primary endpoints: Tolerability of Nozin at 100 days and Incidence of adverse events at 100 days. Started Sep 2019; status: terminated.
02
Drugs
ethanol
03
Conditions
respiratory viral infection
Beyond the preview
Go deeper on NCT04060849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060849.